8-K Announcements
6Material company update
Apr 6, 2026·SEC
Material company update
Feb 26, 2026·SEC
Material company update
Jan 9, 2026·SEC
Heron Therapeutics, Inc.(HRTX)Earnings, Financials & Key Ratios
HRTX•NASDAQ
$1.24
$234M mkt cap·Price updated May 7, 2026
AboutHeron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; HTX-019, an investigational agent for the prevention of postoperative nausea and vomiting; and HTX-034 for postoperative pain management, as well as is in Phase Ib/II clinical study in patients undergoing bunionectomy. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.Show more
- Revenue$155M+7.4%
- EBITDA-$3M+71.9%
- Net Income-$20M-48.7%
- EPS (Diluted)-0.12-34.7%
- Gross Margin73.31%+0.1%
- EBITDA Margin-1.64%+73.8%
- Operating Margin-1.64%+79.5%
- Net Margin-13.04%-38.5%
- ROE-140.9%
- ROIC-1.56%+78.8%
- Debt/Equity9.81
HRTX Key Insights
Heron Therapeutics, Inc. (HRTX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓High quality earnings: Operating CF exceeds net income
- ✓Strong 5Y sales CAGR of 11.8%
✗Weaknesses
- ✗High debt to equity ratio of 9.8x
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Trading more than 30% below 52-week high
- ✗Expensive at 14.4x book value
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
HRTX Price & Volume
Heron Therapeutics, Inc. (HRTX) stock price & volume — 10-year historical chart
Loading chart...
HRTX Growth Metrics
Heron Therapeutics, Inc. (HRTX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years11.81%
3 Years12.89%
TTM7.36%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-48.71%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-34.38%
Return on Capital
10 Years-92.87%
5 Years-51.43%
3 Years-26.94%
Last Year-1.68%
HRTX Recent Earnings
Heron Therapeutics, Inc. (HRTX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)●Beat Revenue 7/12 qtrs (58%)
Q1 2026Latest
Feb 26, 2026EPS
$0.02
Est $0.03
+33.3%
Revenue
$41M
Est $40M
+1.8%
Q4 2025
Nov 4, 2025EPS
$0.05
Est $0.01
-275.1%
Revenue
$38M
Est $39M
-2.1%
Q3 2025
Aug 8, 2025EPS
$0.02
Est $0.01
-100.0%
Revenue
$37M
Est $39M
-4.8%
Q2 2025
May 6, 2025EPS
$0.01
Est $0.01
+200.0%
Revenue
$39M
Est $38M
+1.7%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 26, 2026 | $0.02vs $0.03+33.3% | $41Mvs $40M+1.8% |
| Q4 2025 | Nov 4, 2025 | $0.05vs $0.01-275.1% | $38Mvs $39M-2.1% |
| Q3 2025 | Aug 8, 2025 | $0.02vs $0.01-100.0% | $37Mvs $39M-4.8% |
| Q2 2025 | May 6, 2025 | $0.01vs $0.01+200.0% | $39Mvs $38M+1.7% |
Based on last 12 quarters of dataView full earnings history →
HRTX Peer Comparison
Heron Therapeutics, Inc. (HRTX) competitors in Drug Delivery Technology Platforms — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 PACB | 498.3M | 1.65 | -0.91 | 3.89% | -341.47% | -11.23% | 141.98 | |
 PCRX | 929.88M | 23.64 | 147.75 | 3.63% | 1.27% | 1.31% | 0.66 | |
 ACRS | 585.63M | 4.86 | -9.17 | -58.19% | -8.3% | -62.98% | ||
 JAZZ | 14.24B | 226.96 | -38.86 | 4.88% | 0.66% | 0.71% | 1.26 | |
 MDGL | 12.27B | 534.86 | -41.62 | 432.05% | -27.32% | -50.15% | 0.59 | |
 INVA | 1.93B | 22.80 | 6.91 | 18.52% | 118.91% | 46.47% | 0.23 | |
 PRGO | 1.61B | 11.72 | -1.14 | -2.75% | -43.5% | -50.65% | 1.35 | |
 SUPN | 3.01B | 52.28 | -76.88 | 8.63% | -3.74% | -2.73% | 0.04 |
Compare HRTX vs Peers
Heron Therapeutics, Inc. (HRTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
HRTX Income Statement
Heron Therapeutics, Inc. (HRTX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 30.77M | 77.47M | 145.97M | 88.64M | 86.35M | 107.67M | 127.04M | 144.28M | 154.9M |
| Revenue Growth % | 2305.55% | 151.81% | 88.41% | -39.28% | -2.59% | 24.7% | 17.99% | 13.57% | 7.36% |
| Cost of Goods Sold | 4.59M | 27.51M | 61.62M | 36.19M | 46.02M | 54.87M | 65.11M | 38.65M | 41.35M |
| COGS % of Revenue | 14.91% | 35.51% | 42.21% | 40.83% | 53.3% | 50.96% | 51.25% | 26.79% | 26.69% |
| Gross Profit | 26.18M▲ 0% | 49.96M▲ 90.8% | 84.35M▲ 68.8% | 52.45M▼ 37.8% | 40.33M▼ 23.1% | 52.8M▲ 30.9% | 61.94M▲ 17.3% | 105.64M▲ 70.6% | 113.56M▲ 7.5% |
| Gross Margin % | 85.09% | 64.49% | 57.79% | 59.17% | 46.7% | 49.04% | 48.75% | 73.21% | 73.31% |
| Gross Profit Growth % | 2004.42% | 90.85% | 68.83% | -37.82% | -23.12% | 30.93% | 17.31% | 70.55% | 7.5% |
| Operating Expenses | 220.74M | 233.9M | 295.04M | 280.61M | 258.15M | 227.46M | 172.55M | 117.17M | 116.09M |
| OpEx % of Revenue | 717.45% | 301.91% | 202.13% | 316.58% | 298.98% | 211.25% | 135.82% | 81.2% | 74.95% |
| Selling, General & Admin | 82.16M | 93.87M | 127.66M | 106.08M | 127.33M | 144.75M | 119.82M | 100.48M | 103.67M |
| SG&A % of Revenue | 267.02% | 121.16% | 87.46% | 119.68% | 147.47% | 134.44% | 94.31% | 69.64% | 66.92% |
| Research & Development | 138.58M | 140.03M | 167.38M | 174.53M | 130.82M | 82.7M | 39.13M | 16.68M | 12.43M |
| R&D % of Revenue | 450.42% | 180.75% | 114.67% | 196.91% | 151.51% | 76.81% | 30.8% | 11.56% | 8.02% |
| Other Operating Expenses | -38K | 0 | 0 | 0 | 0 | 0 | 13.6M | 0 | 0 |
| Operating Income | -194.56M▲ 0% | -183.94M▲ 5.5% | -210.69M▼ 14.5% | -228.16M▼ 8.3% | -217.83M▲ 4.5% | -174.66M▲ 19.8% | -110.61M▲ 36.7% | -11.53M▲ 89.6% | -2.54M▲ 78.0% |
| Operating Margin % | -632.36% | -237.42% | -144.34% | -257.41% | -252.27% | -162.21% | -87.07% | -7.99% | -1.64% |
| Operating Income Growth % | -13.83% | 5.46% | -14.55% | -8.29% | 4.53% | 19.82% | 36.67% | 89.58% | 77.98% |
| EBITDA | -193.03M | -182.42M | -208.65M | -225.32M | -214.81M | -171.77M | -107.72M | -9.04M | -2.54M |
| EBITDA Margin % | -627.38% | -235.46% | -142.94% | -254.2% | -248.77% | -159.53% | -84.79% | -6.26% | -1.64% |
| EBITDA Growth % | -13.67% | 5.49% | -14.38% | -7.99% | 4.66% | 20.04% | 37.29% | 91.61% | 71.91% |
| D&A (Non-Cash Add-back) | 1.53M | 1.51M | 2.04M | 2.85M | 3.02M | 2.89M | 2.9M | 2.49M | 0 |
| EBIT | -193.55M | -176.17M | -203.28M | -225.38M | -218.27M | -179.55M | -106.69M | -7.55M | 0 |
| Net Interest Income | -2.89M | 3.29M | 5.79M | 1.73M | -1.98M | -836K | -504K | -2.48M | 0 |
| Interest Income | 1.05M | 5.96M | 7.26M | 3.63M | 433K | 1.64M | 3.36M | 3.55M | 0 |
| Interest Expense | 3.94M | 2.67M | 1.47M | 1.9M | 2.41M | 2.47M | 3.87M | 6.03M | 0 |
| Other Income/Expense | -2.93M | 5.1M | 5.95M | 885K | -2.85M | -7.37M | 56K | -2.05M | -17.66M |
| Pretax Income | -197.48M▲ 0% | -178.84M▲ 9.4% | -204.75M▼ 14.5% | -227.28M▼ 11.0% | -220.68M▲ 2.9% | -182.02M▲ 17.5% | -110.56M▲ 39.3% | -13.58M▲ 87.7% | -20.2M▼ 48.7% |
| Pretax Margin % | -641.87% | -230.84% | -140.27% | -256.41% | -255.58% | -169.05% | -87.02% | -9.41% | -13.04% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -197.48M▲ 0% | -178.84M▲ 9.4% | -204.75M▼ 14.5% | -227.28M▼ 11.0% | -220.68M▲ 2.9% | -182.02M▲ 17.5% | -110.56M▲ 39.3% | -13.58M▲ 87.7% | -20.2M▼ 48.7% |
| Net Margin % | -641.87% | -230.84% | -140.27% | -256.41% | -255.58% | -169.05% | -87.02% | -9.41% | -13.04% |
| Net Income Growth % | -14.06% | 9.44% | -14.49% | -11% | 2.9% | 17.52% | 39.26% | 87.72% | -48.71% |
| Net Income (Continuing) | -197.48M | -178.84M | -204.75M | -227.28M | -220.68M | -182.02M | -110.56M | -13.58M | -20.2M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -3.65▲ 0% | -2.44▲ 33.2% | -2.50▼ 2.5% | -2.50▲ 0.0% | -2.24▲ 10.4% | -1.67▲ 25.4% | -0.80▲ 52.1% | -0.09▲ 88.9% | -0.12▼ 34.7% |
| EPS Growth % | 20.13% | 33.15% | -2.46% | 0% | 10.4% | 25.45% | 52.1% | 88.86% | -34.68% |
| EPS (Basic) | -3.65 | -2.44 | -2.50 | -2.50 | -2.24 | -1.67 | -0.80 | -0.09 | -0.12 |
| Diluted Shares Outstanding | 54.04M | 73.19M | 81.78M | 90.77M | 98.47M | 109M | 138.13M | 152.45M | 166.71M |
| Basic Shares Outstanding | 54.04M | 73.19M | 81.78M | 90.77M | 98.47M | 109M | 138.13M | 152.45M | 166.71M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
HRTX Balance Sheet
Heron Therapeutics, Inc. (HRTX) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 228.06M | 447.25M | 479.06M | 314.2M | 254.42M | 205.44M | 188.77M | 209.01M | 238.07M |
| Cash & Short-Term Investments | 172.38M | 332.37M | 390.97M | 208.49M | 157.58M | 84.85M | 80.41M | 59.28M | 46.63M |
| Cash Only | 144.58M | 31.84M | 71.9M | 105.14M | 90.54M | 15.36M | 28.68M | 25.8M | 28.65M |
| Short-Term Investments | 27.8M | 300.54M | 319.07M | 103.35M | 67.04M | 69.49M | 51.73M | 33.48M | 17.98M |
| Accounts Receivable | 41.87M | 64.65M | 39.88M | 41.85M | 35.5M | 52.05M | 60.14M | 78.88M | 89.59M |
| Days Sales Outstanding | 496.77 | 304.59 | 99.72 | 172.33 | 150.06 | 176.44 | 172.77 | 199.55 | 211.09 |
| Inventory | 10.11M | 39.03M | 24.97M | 41.91M | 48.38M | 54.57M | 42.11M | 53.16M | 92.75M |
| Days Inventory Outstanding | 804.15 | 517.84 | 147.9 | 422.65 | 383.73 | 363 | 236.08 | 502.05 | 818.74 |
| Other Current Assets | 3.7M | 11.19M | 0 | 0 | 0 | 13.96M | 6.12M | 17.69M | 9.1M |
| Total Non-Current Assets | 6.24M | 14.93M | 33.72M | 39.36M | 51.28M | 45.52M | 33.73M | 24.13M | 17.81M |
| Property, Plant & Equipment | 5.98M | 14.68M | 33.37M | 39.01M | 33.56M | 29.8M | 25.6M | 17.65M | 12.4M |
| Fixed Asset Turnover | 5.14x | 5.28x | 4.37x | 2.27x | 2.57x | 3.61x | 4.96x | 8.17x | 12.49x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 263K | 254K | 346K | 346K | 17.72M | 15.71M | 8.13M | 6.48M | 5.41M |
| Total Assets | 234.31M▲ 0% | 462.18M▲ 97.3% | 512.78M▲ 10.9% | 353.56M▼ 31.1% | 305.71M▼ 13.5% | 250.95M▼ 17.9% | 222.51M▼ 11.3% | 233.15M▲ 4.8% | 255.88M▲ 9.7% |
| Asset Turnover | 0.13x | 0.17x | 0.28x | 0.25x | 0.28x | 0.43x | 0.57x | 0.62x | 0.61x |
| Asset Growth % | 247.21% | 97.25% | 10.95% | -31.05% | -13.53% | -17.91% | -11.33% | 4.78% | 9.75% |
| Total Current Liabilities | 103.17M | 92.02M | 96.7M | 102.5M | 71.06M | 82.36M | 79.69M | 91.46M | 96.1M |
| Accounts Payable | 18.77M | 16.86M | 3.07M | 629K | 3.87M | 3.59M | 3.8M | 11.71M | 8.99M |
| Days Payables Outstanding | 1.49K | 223.72 | 18.17 | 6.34 | 30.72 | 23.87 | 21.3 | 110.58 | 79.4 |
| Short-Term Debt | 28.68M | 4.57M | 5.62M | 7.05M | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 2.76M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 44.09M | 780K | 12.2M | 11.91M | 13.48M | 11.28M | 7.85M | 7.96M | 96.1M |
| Current Ratio | 2.21x | 4.86x | 4.95x | 3.07x | 3.58x | 2.49x | 2.37x | 2.29x | 2.48x |
| Quick Ratio | 2.11x | 4.44x | 4.70x | 2.66x | 2.90x | 1.83x | 1.84x | 1.70x | 1.51x |
| Cash Conversion Cycle | -192.26 | 598.71 | 229.44 | 588.64 | 503.07 | 515.57 | 387.56 | 591.02 | 950.43 |
| Total Non-Current Liabilities | 0 | 0 | 12.24M | 14.56M | 157.08M | 155.02M | 176.79M | 175.34M | 145.45M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 149.08M | 149.28M | 173.75M | 174.73M | 140.64M |
| Capital Lease Obligations | 0 | 0 | 12.24M | 14.56M | 8M | 5.5M | 2.8M | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 241K | 241K | 615K | 4.81M |
| Total Liabilities | 103.17M | 92.02M | 108.95M | 117.06M | 228.14M | 237.38M | 256.48M | 266.8M | 241.54M |
| Total Debt | 28.68M | 4.57M | 19.79M | 24.61M | 159.5M | 157.48M | 179.63M | 177.76M | 140.64M |
| Net Debt | -115.9M | -27.26M | -52.11M | -80.53M | 68.95M | 142.11M | 150.95M | 151.96M | 111.99M |
| Debt / Equity | 0.22x | 0.01x | 0.05x | 0.10x | 2.06x | 11.60x | - | - | 9.81x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -49.42x | -68.84x | -143.13x | -120.02x | -90.39x | -70.60x | -28.60x | -1.91x | - |
| Total Equity | 131.14M▲ 0% | 370.16M▲ 182.3% | 403.83M▲ 9.1% | 236.49M▼ 41.4% | 77.57M▼ 67.2% | 13.57M▼ 82.5% | -33.97M▼ 350.3% | -33.65M▲ 0.9% | 14.33M▲ 142.6% |
| Equity Growth % | 717.08% | 182.27% | 9.1% | -41.44% | -67.2% | -82.5% | -350.32% | 0.95% | 142.59% |
| Book Value per Share | 2.43 | 5.06 | 4.94 | 2.61 | 0.79 | 0.12 | -0.25 | -0.22 | 0.09 |
| Total Shareholders' Equity | 131.14M | 370.16M | 403.83M | 236.49M | 77.57M | 13.57M | -33.97M | -33.65M | 14.33M |
| Common Stock | 646K | 782K | 903K | 913K | 1.02M | 1.19M | 1.5M | 1.52M | 1.88M |
| Retained Earnings | -783.46M | -960.72M | -1.17B | -1.39B | -1.61B | -1.8B | -1.91B | -1.92B | -1.94B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -10K | -87K | 85K | 257K | -6K | -19K | 13K | 13K | 4K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
HRTX Cash Flow Statement
Heron Therapeutics, Inc. (HRTX) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -170.3M | -191.81M | -124.58M | -184.82M | -203.35M | -146.91M | -58.79M | -22.53M | -27.59M |
| Operating CF Margin % | -553.52% | -247.57% | -85.35% | -208.51% | -235.51% | -136.44% | -46.27% | -15.61% | -17.81% |
| Operating CF Growth % | -27% | -12.63% | 35.05% | -48.35% | -10.03% | 27.76% | 59.98% | 61.68% | -22.47% |
| Net Income | -197.48M | -178.84M | -204.75M | -227.28M | -220.68M | -182.02M | -110.56M | -13.58M | -20.2M |
| Depreciation & Amortization | 1.53M | 1.51M | 2.04M | 2.85M | 3.02M | 2.89M | 2.9M | 2.49M | 2.31M |
| Stock-Based Compensation | 30.54M | 33.37M | 51.41M | 50.22M | 46.85M | 42.98M | 32.85M | 12.96M | 10.34M |
| Deferred Taxes | -239K | -3.31M | -3.57M | 972K | 1.63M | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 773K | 890K | 1.05M | 1.43M | 904K | -251K | -773K | 3.2M | -20.05M |
| Working Capital Changes | -5.42M | -45.42M | 29.23M | -13.01M | -35.08M | -10.51M | 16.79M | -27.6M | 0 |
| Change in Receivables | -39.91M | -22.78M | 24.77M | -1.97M | 6.35M | -16.55M | -8.09M | -18.74M | -10.71M |
| Change in Inventory | -4.77M | -29.12M | 14.06M | -16.94M | -6.48M | -6.19M | 12.46M | -11.05M | -31.05M |
| Change in Payables | 11.96M | -1.91M | -14.11M | -2.23M | 3.28M | -578K | 15K | 8.47M | -2.71M |
| Cash from Investing | 7.74M | -278.55M | -21.78M | 208.96M | 32.73M | -3.32M | 18M | 18.71M | 16.01M |
| Capital Expenditures | -2.55M | -9.17M | -7.15M | -6.81M | -3.02M | -1.82M | -1.54M | -1.71M | -317K |
| CapEx % of Revenue | 8.3% | 11.84% | 4.9% | 7.69% | 3.5% | 1.7% | 1.22% | 1.18% | 0.2% |
| Acquisitions | 78K | 25K | 0 | 0 | 32K | 227K | 13K | 27K | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 98K |
| Cash from Financing | 293.73M | 357.61M | 186.43M | 9.11M | 156.03M | 75.06M | 54.11M | 940K | 14.43M |
| Debt Issued (Net) | -25M | -25M | 0 | 26K | 148.96M | 0 | 24.35M | 0 | 0 |
| Equity Issued (Net) | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 940K | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 14.43M |
| Net Change in Cash | 131.17M▲ 0% | -112.75M▼ 186.0% | 40.06M▲ 135.5% | 33.24M▼ 17.0% | -14.6M▼ 143.9% | -75.18M▼ 415.0% | 13.31M▲ 117.7% | -2.88M▼ 121.6% | 2.85M▲ 199.0% |
| Free Cash Flow | -172.85M▲ 0% | -200.98M▼ 16.3% | -131.73M▲ 34.5% | -191.63M▼ 45.5% | -206.38M▼ 7.7% | -148.74M▲ 27.9% | -60.33M▲ 59.4% | -24.23M▲ 59.8% | -27.91M▼ 15.2% |
| FCF Margin % | -561.81% | -259.41% | -90.25% | -216.2% | -239.01% | -138.14% | -47.49% | -16.8% | -18.02% |
| FCF Growth % | -25.96% | -16.27% | 34.45% | -45.47% | -7.69% | 27.93% | 59.44% | 59.83% | -15.16% |
| FCF per Share | -3.20 | -2.75 | -1.61 | -2.11 | -2.10 | -1.36 | -0.44 | -0.16 | -0.17 |
| FCF Conversion (FCF/Net Income) | 0.86x | 1.07x | 0.61x | 0.81x | 0.92x | 0.81x | 0.53x | 1.66x | 1.37x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
HRTX Key Ratios
Heron Therapeutics, Inc. (HRTX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -357.52% | -359.44% | -71.35% | -52.91% | -70.99% | -140.53% | -399.43% | - | - | -140.9% |
| Return on Invested Capital (ROIC) | -404.39% | -871.6% | -77.04% | -45.5% | -67.41% | -108.02% | -86.69% | -60.85% | -7.35% | -1.56% |
| Gross Margin | 97.26% | 85.09% | 64.49% | 57.79% | 59.17% | 46.7% | 49.04% | 48.75% | 73.21% | 73.31% |
| Net Margin | -13537.37% | -641.87% | -230.84% | -140.27% | -256.41% | -255.58% | -169.05% | -87.02% | -9.41% | -13.04% |
| Debt / Equity | - | 0.22x | 0.01x | 0.05x | 0.10x | 2.06x | 11.60x | - | - | 9.81x |
| Interest Coverage | -64.16x | -49.42x | -68.84x | -143.13x | -120.02x | -90.39x | -70.60x | -28.60x | -1.91x | - |
| FCF Conversion | 0.77x | 0.86x | 1.07x | 0.61x | 0.81x | 0.92x | 0.81x | 0.53x | 1.66x | 1.37x |
| Revenue Growth | - | 2305.55% | 151.81% | 88.41% | -39.28% | -2.59% | 24.7% | 17.99% | 13.57% | 7.36% |
HRTX SEC Filings & Documents
Heron Therapeutics, Inc. (HRTX) SEC filings — annual & quarterly reports (10-K, 10-Q)
HRTX Frequently Asked Questions
Heron Therapeutics, Inc. (HRTX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Heron Therapeutics, Inc. (HRTX) reported $154.9M in revenue for fiscal year 2025. This represents a 728% increase from $18.7M in 1996.
Heron Therapeutics, Inc. (HRTX) grew revenue by 7.4% over the past year. This is steady growth.
Heron Therapeutics, Inc. (HRTX) reported a net loss of $20.2M for fiscal year 2025.
Dividend & Returns
Heron Therapeutics, Inc. (HRTX) has a return on equity (ROE) of -140.9%. Negative ROE indicates the company is unprofitable.
Heron Therapeutics, Inc. (HRTX) had negative free cash flow of $27.9M in fiscal year 2025, likely due to heavy capital investments.
Explore More HRTX
Heron Therapeutics, Inc. (HRTX) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates